Davendra Sohal, MD of Cleveland Clinic gives an overview of his presentation, Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL.
TPS4152: Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Advertisement